Anaphylaxis News

Healio has compiled October’s most read news in asthma and allergy.

Epinephrine autoinjectors may be associated with short-lived peak plasma levels, unpredictable cardiovascular responses as well as varying epinephrine absorption, according to a review published in Clinical and Experimental Allergy.

Anaphylaxis protocols in emergency medical services have outdated recommendations and guidelines, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — An intranasal epinephrine powder produced responses that were comparable with intramuscular administration, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

California Governor Gavin Newsom signed Elijah’s Law, also known as AB 2317, into law in September, which was drafted to protect children with food allergies who attend childcare centers.

Aquestive Therapeutics expects to finish its final supportive study of its Anaphylm sublingual epinephrine film for the treatment of anaphylaxis by the end of 2024.

ARS Pharmaceuticals announced its submission of a supplemental new drug application to the FDA for neffy 1 mg for the treatment of type 1 allergic reactions in children who weigh between 33 lb and 66 lb.

The Global Allergy and Asthma Excellence Network, or GA2LEN, will host its biannual global meeting from Sept. 5 to 7.

Healio has compiled August’s most-read news in asthma and allergy.

SAN ANTONIO — Recently updated practice parameters will help clinicians better recognize and treat anaphylaxis, Jeffrey Demain, MD, FAAAAI, FACAAI, FAAP, told Healio at the 16th Annual Allergy, Asthma & Immunology CME Conference.